Suppr超能文献

-p.Gly624Asp是欧洲与轻度奥尔波特综合征表型相关的主要变异体。

-p.Gly624Asp is the Predominant Variant in Europe Associated With a Mild Alport Syndrome Phenotype.

作者信息

Krüger Bastian M, Jens Annika, Neuhaus Anna, Ćomić Jasmina, Berutti Riccardo, de Fallois Jonathan, Petzold Friederike, Münch Johannes, Kowald Jan, Lindner Tom H, Budde Klemens, Brüning Klara K, Thumfart Julia, Haas Jacob, Brigl Carolin B, Amann Kerstin, Tasic Velibor, Abazi-Emini Nora, Nushi-Stavileci Valbona, Putnik Jovana, Stajić Nataša, Seelow Evelyn, Hammett Charlotte, Eckardt Kai-Uwe, Riedhammer Korbinian M, Schrezenmeier Eva V, Hoefele Julia, Halbritter Jan

机构信息

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.

出版信息

Kidney Int Rep. 2025 Mar 6;10(5):1372-1383. doi: 10.1016/j.ekir.2025.02.031. eCollection 2025 May.

Abstract

INTRODUCTION

Pathogenic variants in are common causes of inherited kidney disease. The clinical presentation extends from classical Alport syndrome (AS) to focal segmental glomerulosclerosis (FSGS) without extrarenal manifestation. In this study, we aimed to assess the genetic and phenotypic spectrum, along with the associated natural histories, in a cohort of patients with AS from 3 tertiary centers in Central Europe.

METHODS

A total of 210 patients with disease causing variants in one of the genes were characterized and evaluated for genotype-phenotype correlations. In addition, 48 -p.Gly624Asp carriers were analyzed for replication and pooled analysis.

RESULTS

-p.Gly624Asp was by far the most common variant, accounting for 16% of all genetic diagnoses. These patients presented with overall milder renal phenotypes than patients with other missense variants and glycine-missense variants after age- and sex-matching. In patients lacking a wild-type allele (X-Linked AS [XLAS] males and autosomal recessive AS [ARAS]), histological AS was most frequently observed in kidney biopsies, and truncating variants were associated with increased disease severity. Conversely, in patients with a wild-type allele present (XLAS females and autosomal dominant AS [ADAS]), FSGS was more frequently observed. Predicted protein truncation was not inferior to missense alterations in terms of renal survival.

CONCLUSION

The predominance of the European founder variant p.Gly624Asp allowed for the creation of the largest cohort of patients with an identical Alport variant to date, confirming the more favorable renal prognosis specific to this amino acid change. Allelic and gene dosage effects drive phenotypic differences and should be incorporated into future risk models.

摘要

引言

[相关基因]中的致病变异是遗传性肾病的常见病因。临床表现从典型的阿尔波特综合征(AS)到无肾外表现的局灶节段性肾小球硬化(FSGS)不等。在本研究中,我们旨在评估来自中欧3个三级中心的AS患者队列中的基因和表型谱以及相关的自然病史。

方法

对总共210例在[相关基因]之一中携带致病变异的患者进行了特征分析,并评估了基因型与表型的相关性。此外,对48例-p.Gly624Asp携带者进行了重复分析和汇总分析。

结果

-p.Gly624Asp是迄今为止最常见的变异,占所有基因诊断的16%。在年龄和性别匹配后,这些患者的肾脏表型总体上比其他[相关基因]错义变异和[相关基因]甘氨酸错义变异的患者更轻。在缺乏野生型等位基因的患者(X连锁AS [XLAS]男性和常染色体隐性AS [ARAS])中,肾脏活检最常观察到组织学AS,而截短变异与疾病严重程度增加相关。相反,在存在野生型等位基因的患者(XLAS女性和常染色体显性AS [ADAS])中,FSGS更常被观察到。就肾脏存活率而言,预测的蛋白质截短并不逊色于错义改变。

结论

欧洲[相关基因]始祖变异-p.Gly624Asp的优势使得能够建立迄今为止最大的具有相同阿尔波特变异的患者队列,证实了这种氨基酸变化所特有的更有利的肾脏预后。等位基因和基因剂量效应驱动表型差异,应纳入未来的风险模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a098/12142618/1a08f9129a3c/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验